Endurant Capital Management’s Coherus Oncology CHRS Stock Holding History

Endurant Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-64,956	Closed	-$444K	–	42
2023 Q1	$444K	Buy	+64,956	New	+$504K	0.23%	43
2016 Q4	–	Sell	-8,400	Closed	-$225K	–	78
2016 Q3	$225K	Buy	+8,400	New	+$229K	0.08%	93

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Endurant Capital Management's CHRS Position: Q2 2023 in Review

Endurant Capital Management sold out of Coherus Oncology (CHRS) in Q2 2023, closing a stake of 64,956 shares — an estimated $444K sold.

Endurant Capital Management first reported a position in CHRS in Q3 2016 and held it in 2 quarters. The position peaked at $444K in Q1 2023. 161 funds tracked by Wall St. Rank hold CHRS as of Q2 2023.

Endurant Capital Management reported no remaining Coherus Oncology position as of Q2 2023 after selling out during the quarter.
Endurant Capital Management sold 64,956 Coherus Oncology shares in Q2 2023, an estimated $444K.
Endurant Capital Management first reported a position in Coherus Oncology in Q3 2016 and held it in 2 quarters.
Endurant Capital Management's Coherus Oncology position peaked at $444K in Q1 2023.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2023.

Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.